All Stories

  1. Quality standards for the management of bronchiectasis in Italy: a national audit
  2. Clinical phenotypes in adult patients with bronchiectasis
  3. Etiology of bronchiectasis
  4. Corrigendum to “De-escalation therapy among bacteraemic patients with community-acquired pneumonia” [Clin Microbiol Infect 21 (2015) 936.e11–936.e18]
  5. De-escalation therapy among bacteraemic patients with community-acquired pneumonia
  6. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response
  7. A Comprehensive Analysis of the Impact ofPseudomonas aeruginosaColonisation on Prognosis in Adult Bronchiectasis
  8. Epidemiology of clinical trials in respiratory diseases in Europe and Italy
  9. Research priorities in bronchiectasis: A consensus from the European multicentre bronchiectasis audit and research collaboration (EMBARC) study group
  10. Patients in randomized clinical trials of bronchiectasis are only partially representative of clinical practice: A European cohort study
  11. Heterogeneity in bronchiectasis service provision in Europe: Baseline data from the European bronchiectasis registry (EMBARC)
  12. Acute myocardial infarctionversusother cardiovascular events in community-acquired pneumonia
  13. Chromogranin A levels and mortality in patients with severe sepsis
  14. How to choose the duration of antibiotic therapy in patients with pneumonia
  15. Challenges in the development of new therapies for bronchiectasis
  16. Management of bronchiectasis in adults
  17. Towards tuberculosis elimination: an action framework for low-incidence countries
  18. Supporting clinical management of the difficult-to-treat TB cases: the ERS-WHO TB Consilium
  19. Chronic infection with non-tuberculous mycobacteria in patients with non-CF bronchiectasis: Comparison with other pathogens
  20. Delirium symptoms during hospitalization predict long-term mortality in patients with severe pneumonia
  21. Nontuberculous Mycobacteria: Epidemiologic, Mycobacteriologic, and Clinical Aspects
  22. Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis
  23. Drug-resistant pathogens in community-acquired pneumonia
  24. Tuberculosis
  25. Dyspnea in crackling lungs
  26. Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases
  27. European Respiratory Monographs: Community Acquired Pneumonia. Edited by J. D. Chalmers , M. W. Pletz and S. Aliberti (Pp. 289; €55; ISBN 978-1-849-84049-1.) European Respiratory Society. March 2014.
  28. COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity?
  29. Antiplatelets Improve Survival Among Critically Ill Mechanically Ventilated Patients
  30. Clustering Non-Cystic Fibrosis Bronchiectasis (NCFBE) Patients According to Clinical Features
  31. Pneumococcal Vaccine and Patients with Pulmonary Diseases
  32. The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients
  33. Preventing Arterial Catheter-Associated Bloodstream Infections
  34. Cardiac diseases complicating community-acquired pneumonia
  35. Erratum to: Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia
  36. Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia
  37. The role of vaccination in preventing pneumococcal disease in adults
  38. The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: Results from the Community-Acquired Pneumonia Org...
  39. Management of nontuberculous mycobacterial infection in the elderly
  40. Is it time for a “pneumo-geriatrician” for frail old patients with respiratory diseases?
  41. The management of community-acquired pneumonia in the elderly
  42. Geriatric multidimensional assessment for elderly patients with acute respiratory diseases
  43. Community-Acquired Pneumonia
  44. Introduction
  45. Early outcomes in CAP: clinical stability, clinical failure and nonresolving pneumonia
  46. Validation of a Disease Specific Severity Index for Non-Cystic Fibrosis Bronchiectasis: The BSI Index
  47. The Bronchiectasis Severity Index. An International Derivation and Validation Study
  48. Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia
  49. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis
  50. Influenza A/H1N1 Severe Pneumonia: Novel Morphocytological Findings in Bronchoalveolar Lavage
  51. TB elimination: a dream or a reality? Key lessons from the ERS external course in Dubrovnik, Croatia
  52. Editorial Commentary: Healthcare-Associated Pneumonia: Where Do We Go Next?
  53. S124 Derivation and validation of the bronchiectasis severity index: an international multicentre observational study
  54. The Changing Microbiologic Epidemiology of Community-Acquired Pneumonia
  55. Idiopathic Bronchiectasis Less Common Than Predicted: Quality Improvement Project
  56. Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia
  57. Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia
  58. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table 1
  59. The Spectrum of Bronchial Infection
  60. Impact of exacerbations in the natural course of COPD
  61. Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes
  62. Microbiological Diagnosis and Antibiotic Therapy in Patients with Community-Acquired Pneumonia and Acute COPD Exacerbation in Daily Clinical Practice: Comparison to Current Guidelines
  63. Hospital Admission Decision for Patients with Community-Acquired Pneumonia
  64. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia
  65. A 61-year-old female with chronic cough and purulent sputum
  66. Diaphragm ultrasonography in the management of patients with amyotrophic lateral sclerosis
  67. Should Health Care Systems and Health Care Providers Implement a New Pathway for Hospitalized Patients With Community-Acquired Pneumonia?
  68. Criteria for clinical stability in hospitalised patients with community-acquired pneumonia
  69. Compliance with anti-H1N1 vaccine among healthcare workers and general population
  70. The role of lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia
  71. The role of biomarkers in low respiratory tract infections
  72. The management of patients with community-acquired pneumonia beyond antibiotic therapy
  73. Antibiotics as immunomodulant agents in COPD
  74. Clinical Stability versus Clinical Failure in Patients with Community-Acquired Pneumonia
  75. Pneumonia in the Community Caused by Multidrug-Resistant Organisms: Keep Working on Probabilistic Scores
  76. Stratifying Risk Factors for Multidrug-Resistant Pathogens in Hospitalized Patients Coming From the Community With Pneumonia
  77. Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia
  78. Noninvasive ventilation or continuous positive airway pressure in pulmonary edema patients with respiratory acidosis? Look at the bicarbonates
  79. Association Between Time to Clinical Stability and Outcomes After Discharge in Hospitalized Patients With Community-Acquired Pneumonia
  80. Where are the acutely ill best cared for and who should look after them?
  81. Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia
  82. Early application of non-invasive continuous positive airway pressure in acute respiratory distress syndrome due to a drug overdose: a case report
  83. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy
  84. Acidemia does not affect outcomes of patients with acute cardiogenic pulmonary edema treated with continuous positive airway pressure
  85. Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
  86. Bronchiectasis: an update
  87. O papel da neutropenia no prognóstico do doente oncológico com pneumonia adquirida na comunidade**Eur Respir J 2009; 33:142-147
  88. O papel da neutropenia no prognóstico do doente oncológico com pneumonia adquirida na comunidade
  89. Acute effects of positive end-expiratory pressure on left ventricle diastolic function in healthy subjects
  90. Usefulness of simplified acute physiology score II in predicting mortality in patients admitted to an emergency medicine ward
  91. Chlamydophila pneumoniae
  92. The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia
  93. Incidence, Etiology, Timing, and Risk Factors for Clinical Failure in Hospitalized Patients With Community-Acquired Pneumonia
  94. Mortality in acute cardiogenic pulmonary edema treated with continuous positive airway pressure
  95. Acute Myocardial Infarction in Hospitalized Patients with Community‐Acquired Pneumonia
  96. Impact of neutrophil function on outcomes of community-acquired pneumonia in patients with cancer
  97. Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infection
  98. 100 years of respiratory medicine: Pneumonia
  99. Prulifloxacin: a brief review of its potential in the treatment of acute exacerbation of chronic bronchitis
  100. Antibiotic therapy and prophylaxis in COPD
  101. Mixed community-acquired lower respiratory tract infections
  102. Chlamydophila pneumoniae induces a sustained airway hyperresponsiveness and inflammation in mice
  103. A 13-year-old female with shortness of breath and pleuritic chest pain
  104. Telithromycin in lower respiratory tract infections
  105. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections
  106. Azithromycin and lower respiratory tract infections
  107. Strategic Targets of Essential Host-Pathogen Interactions
  108. Chlamydia pneumoniae and Mycoplasma pneumoniae